product name BLU-554 (BLU554)
Description: BLU-554 is a potent, highly-selective, orally available FGFR4 inhibitor with an IC50 value of 5 nM. BLU-554 has the potential to be used for the treatment of hepatocellular carcinoma and cholangiocarcinoma. BLU-554 is well tolerated in these tumor models. Administration of BLU-554 induces tumor regression in liver cancer models.
References: PCT Int. Appl. (2015), WO 2015061572 A1 20150430.; Blueprint Medicines. 50th th international liver congress. 2015.
503.38
Formula
C24H24Cl2N4O4
CAS No.
1707289-21-1
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: 100 mg/mL (198.7 mM)
Water: <1 mg/mL
Ethanol: 2 mg/mL (4 mM)
Solubility (In vivo)
Synonyms
other peoduct :References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/19420933
| In Vitro |
In vitro activity: BLU-554 exploits a unique interaction with FGFR4 to confer potency and selectivity. Kinase Assay: Cell Assay: |
|---|---|
| In Vivo | BLU-554 is well tolerated in these tumor models. Administration of BLU-554 induces tumor regression in liver cancer models |
| Animal model | |
| Formulation & Dosage | |
| References | PCT Int. Appl. (2015), WO 2015061572 A1 20150430.; Blueprint Medicines. 50th th international liver congress. 2015. |
